PBDA Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Protalix Biotherapeutics Inc

Watchlist Manager

Watchlist

Price: 2.26 EUR 2.49%

Market Cap: €165.7m

	Protalix Biotherapeutics Inc F:PBDA	US
	Triboo SpA MIL:TB	IT
	SGS SA OTC:SGSOF	CH

Profitability Summary

Protalix Biotherapeutics Inc's profitability score is 62/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

69%

Strong 3Y Average Gross Margin

56%

Declining Gross Margin

72% > 69%

Healthy Operating Margin

29%

Low 3Y Average Operating Margin

Operating Margin is Increasing

18% > 29%

Healthy Net Margin

23%

Low 3Y Average Net Margin

Net Margin is Increasing

13% > 23%

Healthy Free Cash Flow Margin

10%

Negative 3Y Average Free Cash Flow Margin

-1%

Free Cash Flow Margin is Increasing

-16% > 10%

Exceptional ROE

31%

Positive 3Y Average ROE

Positive 3Y Average ROIC

10%

ROIC is Increasing

28% > 37%

View All

Hide

Collapse

62 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.